

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 7/62, C07C 69/65	A1	(11) International Publication Number: WO 97/22710 (43) International Publication Date: 26 June 1997 (26.06.97)
<p>(21) International Application Number: PCT/US96/19423</p> <p>(22) International Filing Date: 18 December 1996 (18.12.96)</p> <p>(30) Priority Data: 08/575,334 20 December 1995 (20.12.95) US</p> <p>(71) Applicant: SHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).</p> <p>(72) Inventors: NIELSEN, Christopher, M.; 101 Joseph Lane, Mine Hill, NJ 07803 (US). SUDHAKAR, Anantha; 18 Snowden Road, East Brunswick, NJ 08816 (US).</p> <p>(74) Agents: JEANETTE, Henry, C. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF ANTIFUNGAL AGENTS</p> <p>(57) Abstract</p> <p>A process for producing a crystalline chiral hydroxy ester of formula (1.0) is disclosed. The process comprises reacting a diol of formula (2.0), with an effective amount of isobutyric anhydride and an effective amount of a lipase enzyme in an effective amount of acetonitrile, said reaction being conducted at a low temperature, and wherein X¹ and X² are each independently selected from F or Cl.</p> <div data-bbox="1166 1610 1799 2024"></div> <div data-bbox="1225 2116 1760 2487"></div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5


**PROCESS FOR PREPARING INTERMEDIATES FOR THE
SYNTHESIS OF ANTIFUNGAL AGENTS**

10


BACKGROUND OF THE INVENTION

U.S. 5,403,937, issued April 4, 1995, and WO/94/25452, published November 10, 1994, disclose a process for making intermediates for the synthesis of antifungal agents. It is

15 disclosed that compounds of the formula:



can be treated with a mild acylating agent, preferably an ester of the formula R¹-C(O)-OR³ (wherein R¹ is C₁ to C₆ alkyl, aryl or -(CH₂)_nCO₂H, wherein n is 1, 2, 3 or 4, and R³ is trifluoroethyl, C₁-C₆ alkyl or C₂-C₆ alkenyl), most preferably vinyl acetate, in the
20 presence of an enzyme, most preferably Novo SP435, in a suitable solvent, such as toluene or CH₃CN, at 0° to 35°C, preferably about 25°C, to form the chiral hydroxy ester of the formula :



25 wherein X¹ and X² in the above formulas are independently F or Cl.


In view of the interest in obtaining chiral hydroxy esters in a large enantiomeric excess, a process for providing such esters would be a welcome contribution to the art. The invention described herein provides just such a process.

5


SUMMARY OF THE INVENTION

This invention provides a process for preparing the crystalline chiral hydroxy esters of Formula 1.0 by the stereoselective acylation of a diol of Formula 2.0 with isobutyric anhydride. The process comprises reacting a diol of Formula 2.0 with isobutyric anhydride and a lipase enzyme in a suitable organic solvent (e.g., acetonitrile) at a low temperature. A sufficient amount of enzyme and isobutyric anhydride is used to allow the reaction to proceed at a reasonable rate to the formation of the chiral hydroxy ester while keeping the formation of diesters to a minimum.

Thus, this invention is directed to a process for preparing a crystalline chiral hydroxy ester of the formula:



20 comprising reacting a diol of the formula:



with an effective amount of isobutyric anhydride and an effective catalytic amount of a lipase enzyme in a suitable organic solvent, said reaction being conducted at a low temperature, and wherein X¹ and X² are each independently selected from F or Cl.

25

DETAILED DESCRIPTION OF THE INVENTION

The reaction of the diol (2.0) with isobutyric anhydride and the lipase enzyme is preferably conducted under an inert atmosphere, such as nitrogen. Also, it is preferred that the
5 reaction be conducted under anhydrous conditions.

In the compounds of Formulas 1.0 and 2.0, X¹ and X² are each preferably F.

The diol of Formula 2.0 can be prepared according to the methods described in U.S. 5,403,937, issued April 4, 1995, and
10 WO/94/25452, published November 10, 1994; the disclosures of each being incorporated herein by reference thereto.

The isobutyric anhydride (hereinafter "anhydride") is used in an effective amount, i.e., an amount which effectively provides the mono chiral hydroxy ester of Formula 1.0 while avoiding the
15 formation of diester. If an insufficient amount of anhydride is used the desired enantiomeric excess (hereinafter "e.e.") is not obtained. If an unquenched excess of anhydride is used then larger amounts of diester are formed.

Generally, at least about one mole equivalent (Meq) of
20 anhydride is used, with about 1 to about 1.1 Meq being preferred, and about 1.05 to about 1.1 Meq being more preferred, and about 1.1 Meq being most preferred.

An excess of anhydride (i.e., an amount greater than 1.1 Meq) can be used provided that a suitable quenching reagent is
25 added to the reaction mixture as soon as the desired e.e. is obtained. The quenching reagent stops the reaction by reacting with the remaining anhydride. Thus, the anhydride can be used in an amount of about 1 Meq to about 3 Meq, provided that when amounts greater than 1.1 Meq are used a suitable quenching
30 reagent is added to the reaction mixture as soon as the desired e.e. is obtained--i.e., as soon as an e.e. of about 97 to about 100% is obtained. The quenching reagent is added in a sufficient amount to react with (i.e., consume) the remaining anhydride so as to stop the reaction. Suitable quenching reagents include but
35 are not limited to water and alcohols (e.g., a C₁ to C₃ alkanol, such as methanol, ethanol, propanol or isopropanol).

The lipase enzyme used is one that can catalyze the esterification of a symmetrical prochiral diol (e.g., Formula 2.0),

- 4 -

such that a single chiral hydroxy ester (e.g., Formula 1.0) is formed in high e.e. The preferred enzyme preparation to produce the S-monoester was commercially available under the product designation NOVO SP435 (Candida antartica, Novozym 5 435 from Novo Nordisk). Those skilled in the art will appreciate that this is an immobilized form of Candida antartica. This enzyme is reported to be a triacylglycerol hydrolase (E.C. no. 3.1.1.3) and at the same time it acts as an effective carboxylesterase.

10 The enzyme is used in an effective catalytic amount--i.e., an amount which effectively catalyzes, at a reasonable rate of reaction, the esterification of the diol of Formula 2.0 to the hydroxy ester of Formula 1.0. Those skilled in the art will appreciate that the enzyme can be used in amounts of about 1 to 15 about 100 wt% (relative to the charge of diol 2.0). Generally, the enzyme is used in amounts of about 1 to about 25 wt%, with about 1 to about 10 wt% being preferred, and about 3 to about 7 wt% being more preferred, and about 5 wt% being most preferred.

Suitable organic solvents include but are not limited to THF 20 (tetrahydrofuran), ethyl acetate, acetonitrile, toluene and methylene chloride. Preferably, acetonitrile is used. It will be appreciated by those skilled in the art that the solvent is used in an amount which effectively dissolves the reactants and allows the reaction to proceed at a reasonable rate. For example, a solvent, 25 such as acetonitrile, can be used in an amount of at least about 5 wt volumes (i.e., a volume that is in an excess of at least 5 times (5X) the amount of diol 2.0), with about 5 wt volumes being preferred.

Acetonitrile may contain residual water (e.g., about 0.03 to 30 about 0.05%) which could react with the anhydride. The amount of anhydride used takes into consideration any water that may be present in the acetonitrile. For example, the use of 1.1 Meq of anhydride takes into consideration the reaction of about 0.05 Meq of anhydride with residual water in the acetonitrile and the 35 reaction of about 1.05 Meq of anhydride with the diol 2.0.


The reaction is conducted at a temperature low enough to reduce the formation of unwanted by-products, but not so low as to require an unreasonably long reaction time. A suitable

temperature is about -15 to about +5°C, with about -15 to about 0°C being preferred.

If desired the hydroxy ester 1.0 can be isolated by techniques well known to those skilled in the art. For example, isolation can be accomplished using an aqueous bicarbonate and water work-up followed by solvent replacement, in vacuo, with heptane.

The examples that follow are intended to exemplify the claimed invention, and should not be construed as limiting the disclosure or the claimed invention.

EXAMPLE 1



Under nitrogen, the diol 2.1 (80 g) was dissolved in 400 ml (5 volumes) of dry acetonitrile. To this solution, 58.9 g of sodium bicarbonate and 4.0 g of Novozym SP 435 were added and the mixture was cooled to a temperature between -10 and -15°C. When the mixture was cool, 62.88 g of 97% pure isobutyric anhydride was charged to the stirring solution while maintaining the temperature. After stirring isothermally for about 20 hours, the desired e.e.% was obtained along with a diester level of about 4%. The reaction was filtered through celite and the filter cake was washed with two 25 ml portions of acetonitrile. The solution was diluted with 800 ml (10 volumes) of methyl t-butyl ether and then washed with three successive 600 ml portions of 5% aqueous bicarbonate and twice with successive 600 ml portions of deionized water until the final pH was between 6.5 and 7. The solution was concentrated in vacuo followed by solvent replacement with heptane in vacuo to give a slurry of white solid in heptane. The volume was brought to 750 ml (9 volumes) with heptane. This mixture was heated to 50°C to 60°C give a solution.


- 6 -

A thick slurry was obtained by cooling slowly to ambient temperature, followed by cooling in an ice/acetone bath to -12°C. After stirring for 30 minutes, the product was isolated by vacuum filtration and washed with 80 ml (1 volume) of -10°C heptane.

- 5 This yielded, after vacuum drying at ambient temperature, the hydroxy ester 1.1, 95.3 g (91% of theory) of white needles that had a purity of 99% and a corrected e.e.% of 99.4%. Corrected e.e.% = (S-ester% - R-ester%)/(S-ester% + R-ester% + diol 2.1). An additional 5 g of the hydroxy ester 1.1 (5% of theory,
- 10 corrected e.e.% = 97.9%) was isolated from the mother liquors by concentration and filtration. ¹H-NMR (400 MHz, CDCl₃): δ 7.53-7.47 (m, 1H), 6.91-6.86 (m, 1H), 6.83-6.78 (m, 1H), 4.17-4.13 (dd, 1H), 4.09-4.04 (m, 2H), 3.87-3.84 (dd, 1H), 3.69 (s, 2H), 2.59-2.53 (m, 3H), 2.19-2.12 (dd, 1H), 1.17 (s, 3H), 1.15 (s, 3H).

15

EXAMPLE 2



- Under nitrogen, the diol (2.1), 8 Kg, was dissolved in 40 liters (5X) of acetonitrile. The resulting mixture showed 0.9% water by Karl Fischer analysis. This corresponds to 8 mol% water. Sodium bicarbonate USP, 5.6 Kg, was charged and the solution was cooled to about -10°C. Novozyme SP 435, 400 grams, was charged to the cooled solution. Isobutyric anhydride, 5.92 Kg (1.1 equivalents), was charged and the reaction mixture
- 20 was stirred overnight at about -10°C. After 16 hours, the enzymatic acylation yielded a mixture that had an e.e.% of 98.3% and contained 4% diester and 0.6% diol (2.1).


- HPLC analysis performed using a Chiralpak AS column (4.6 mm x 250 mm), 5% ethanol in heptane as the solvent, a flow rate
- 30 of 1 mL per minute, and a detector set to a wavelength of 215 nm

yielded the following results for a sample taken at 16 hours: 0.4% starting material; 3.9% diester; 94.8% S-ester; and 0.8% R-ester.

EXAMPLE 3

COMPARATIVE EXAMPLE

5




Under nitrogen, the diol (2.1), 33 kg, was dissolved in 165 liters of acetonitrile. Novozyme SP 435, 1.65 Kg, was charged to the solution and the reaction mixture was cooled to between about 0° to about 5°C. Vinyl acetate, 19.8 Kg, was added to the
10 agitating solution. After 4.5 hours, the enzyme was removed from the reaction mixture by filtration through a sparkler.

The reaction was monitored by HPLC using a Chiralpak AS column (4.6 mm x 250 mm), 5% ethanol in heptane as the
15 solvent, a flow rate of 1 mL per minute, and a detector set to a wavelength of 215 nm. At 4.5 hours, HPLC yielded the following results: 0.4% starting material; 31.0% diester; 68.0% S-ester; 0.5% R-ester; and an e.e.% of 98.4.


20 While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit
25 and scope of the present invention.

WHAT IS CLAIMED IS:

1. A process for producing a crystalline chiral hydroxy ester of the formula:



comprising reacting a diol of the formula:



with an effective amount of isobutyric anhydride and an effective catalytic amount of a lipase enzyme in a suitable organic solvent, said reaction being conducted at a low temperature, and wherein X¹ and X² are each independently selected from F or Cl.

2. The process of Claim 1 wherein X¹ and X² are F.

3. The process of Claim 1 wherein said isobutyric anhydride is used in amounts of about 1.05 to about 1.1 Meq.

4. The process of Claim 1 wherein the enzyme used is NOVO SP435.

5. The process of Claim 4 wherein said enzyme is used in amounts of about 3 to about 5 wt% based on the charge of diol.

6. The process of Claim 1 wherein said organic solvent is acetonitrile.

- 9 -

7. The process of Claim 1 wherein the reaction is conducted at a temperature of about -15 to about +5°C.

5 8. The process of Claim 1 wherein the reaction is conducted at a temperature of about -15 to about 0°C.

9. The process of Claim 1 wherein the enzyme used is NOVO SP435, and the reaction is conducted at a temperature of about -15 to about +5°C.
10

10. The process of Claim 9 wherein the enzyme is used in amounts of about 3 to about 7 wt% based on the charge of diol 2.0, and the isobutyric anhydride is used in amounts of about 1.05 to about 1.1 Meq.
15

11. The process of Claim 10 wherein the organic solvent is acetonitrile.

12. The process of Claim 11 wherein the enzyme is used
20 in an amount of about 5 wt% based in the charge of diol 2.0.

13. The process of Claim 12 wherein the reaction is conducted at a temperature of about -15 to about 0°C.

25 14. The process of Claim 10 wherein X¹ and X² are F.

15. The process of Claim 11 wherein X¹ and X² are F.

16. The process of Claim 12 wherein X¹ and X² are F.
30

17. The process of Claim 13 wherein X¹ and X² are F.

INTERNATIONAL SEARCH REPORT

Intern: al Application No
PCT/US 96/19423

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12P7/62 C07C69/65

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12P C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 25452 A (SCHERING CORP ;SAKSENA ANIL K (US); GIRIJAVALLABHAN VIYYOOR M (US)) 10 November 1994 cited in the application see the whole document (see especially Claims 2,3,11 and 12)	1-17
Y	TETRAHEDRON LETTERS, vol. 36, 13 March 1995, pages 1787-1790, XP000652682 SAKSENA A.K. ET AL.: "HIGHLY STEREOSELECTIVE ACCESS TO NOVEL 2,2,4-TRISUBSTITUTED TETRAHYDROFURANS BY HALOCYCLIZATION: PRACTICAL CHEMOENZYMATIC SYNTHESIS OF SCH 51048, A BROAD-SPECTRUM ORALLY ACTIVE ANTIFUNGAL AGENT" see page 1788	1-17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>
--	--

2

Date of the actual completion of the international search 16 April 1997	Date of mailing of the international search report 14.05.97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Olsen, L

Internal Application No
PCT/US 96/19423

[illegible]

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/19423

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9425452 A	10-11-94	US 5403937 A	04-04-95
		AU 6667194 A	21-11-94
		CA 2161662 A	10-11-94
		CN 1122134 A	08-05-96
		CZ 9502843 A	17-04-96
		EP 0696282 A	14-02-96
		FI 955119 A	27-10-95
		HU 73760 A	30-09-96
		JP 8509730 T	15-10-96
		NO 954314 A	02-01-96
		PL 311267 A	05-02-96
		SK 134295 A	06-11-96
WO 9322451 A	11-11-93	AU 3978193 A	29-11-93
		US 5326885 A	05-07-94
WO 9530638 A	16-11-95	US 5442093 A	15-08-95
		AU 2462495 A	29-11-95
		CA 2189128 A	16-11-95
		EP 0759024 A	26-02-97